AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 162 min read$ALHC

Maroney Dawn Christine sold $3.7M of ALHC

Maroney Dawn Christine (President) sold 177,068 shares of Alignment Healthcare, Inc. (ALHC) at $20.83 ($3.69M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maroney Dawn Christine
Published Jul 16, 2026, 8:54 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 16, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ALHC
Neutral
medium confidence
Mentioned
$ALHC
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCNeutralLow
01

Why it matters

The disclosure updates the record of insider activity, but it does not introduce new operational, financial, or regulatory information about ALHC.

02

Market read

Traders may monitor insider activity for sentiment, but this specific filing is unlikely to drive a fundamental repricing.

03

What to watch

Insider sales can be offset by other insider buys or option exercises not shown here; also, the filing does not reveal whether future sales are scheduled beyond the current plan.

Relevance 5/10Novelty 3/10Timing: after-hours, following the 2026-07-16 Form 4 filing disclosure

Background

The article is a primary-source SEC Form 4 insider transaction for Alignment Healthcare, Inc. (ALHC).

Company-level read

Ticker impact

$ALHCNeutralMedium confidence
Context

Alignment Healthcare disclosed a Form 4 sale by President Maroney Dawn Christine of 177,068 shares at $20.8281 on 2026-07-15 under a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing provides transaction size, price, and 10b5-1 status, but no new company fundamentals, guidance, or regulatory/legal developments.

Market effects

Sector

No direct sector read-across; this is company-specific insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could reflect routine liquidity planning rather than negative expectations, especially because it is explicitly under a 10b5-1 plan.

Key entities

  • issuer
    Alignment Healthcare, Inc.

    Company whose insider transaction was reported on SEC Form 4.

  • insider
    Maroney Dawn Christine

    President and reporting officer who sold shares.

  • trading mechanism
    10b5-1 plan

    Pre-arranged plan that reduces the interpretive weight of the sale timing.

Read at source← All news

Related articles

AUG 7
$ALHCMed

Can ALHC's Raised 2026 Outlook Offset Heavier Second-Half Spending?

Alignment Healthcare (ALHC) reported Q2 EPS of 17 cents, up from 7 cents a year earlier, with revenue rising 31.6% to $1.34B and beating consensus. Membership reached about 294,100. The company raised 2026 guidance to $5.195B-$5.225B revenue and 298,000-301,000 membership, but expects lower Q3 adjusted EBITDA ($20M-$30M) due to added clinical, AI and expansion spending.

finance.yahoo.com6 min
AUG 3
$ALHCMed

Kaplan Fox Reminds Alignment Healthcare, Inc. (NASDAQ: ALHC) Investors of an Investigation Into Potential Securities Law Violations

Kaplan Fox said a former Alignment Healthcare executive filed a whistleblower complaint alleging accounting irregularities that allegedly inflated reported and projected results, including Adjusted EBITDA, and misclassified operating expenses as capital expenditures. After the July 8, 2026 report, ALHC shares fell $4.02, or 16.7%, to close at $20.03, according to the article.

theglobeandmail.com3 min
JUL 31
$ALHCMed

Alignment Healthcare (ALHC) Stock Trades Down, Here Is Why

Alignment Healthcare (ALHC) shares fell 14.8% after the company said it will reinvest profits, lowering expected second-half 2026 earnings. On its Q2 2026 call, management raised full-year revenue guidance but expects only about 30% of adjusted EBITDA in the second half, versus 40% a year earlier, due to investment timing.

financialcontent.com3 min
JUL 31
$ALHCHighAI 9/10

Alignment Healthcare (ALHC) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 5:00 p.m. ET CALL PARTICIPANTS Executive Chairman and Chief Executive Officer - John E. Kao Chief Financial Officer - James Head TAKEAWAYS Health Plan Membership -- 294,000 members, representing 31% growth year over year. Total Revenue -- $1.3 billion, an increase of 32% year over year driven by membership growth. Adjusted MBR -- 86.3%, an improvement of 40 basis points year over year and the lowest since the company went public.

fool.com6 min
JUL 31
$ALHCHighAI 9/10

Alignment Misses Q2 EPS Estimates

Stock falls 12% in after-hours trading Shares in Alignment Healthcare fell 12% in after-hours trading after reporting second quarter results. Orange-based Alignment, a Medicare Advantage provider for seniors, reported earnings per share (EPS) of 17 cents, missing the 20-cent consensus estimate, according to the TheFly.com. The company’s third-quarter revenue outlook of $1.3 billion to $1.32 billion also came in at the low end of Wall Street estimates.

ocbj.com2 min
JUL 30
$ALHCMedAI 8/10

Alignment Healthcare (NASDAQ:ALHC) Beats Q2 CY2026 Sales Expectations But Stock Drops

Health insurance company Alignment Healthcare (NASDAQ: ALHC) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 31.6% year on year to $1.34 billion. The company expects next quarter’s revenue to be around $1.31 billion, close to analysts’ estimates. Its GAAP profit of $0.17 per share was 29.8% above analysts’ consensus estimates. Is now the time to buy Alignment Healthcare? Find out by accessing our full research report, it’s free.

financialcontent.com4 min